# Advances and future perspectives in the treatment and prognosis of type 1 diabetes mellitus

## TL;DR

This paper reviews recent advances in treating and managing type 1 diabetes, focusing on new therapies and challenges in implementing them in China.

## Contribution

The paper provides a comprehensive review of emerging therapies and challenges specific to the Chinese healthcare system for T1DM.

## Key findings

- Novel insulin formulations and automated delivery systems are improving T1DM management.
- Immunomodulatory and gene-edited stem cell therapies show promise for restoring β-cell function.
- Phytomedicines and gut microbiota modulation are being explored as potential treatment avenues.

## Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic β-cells, necessitating lifelong exogenous insulin. This review synthesizes key advances that are shifting T1DM management from symptomatic control to disease modification and potential cure. We examine progress in novel insulin formulations and automated insulin delivery systems, alongside groundbreaking immunomodulatory therapies and gene-edited stem cell therapies that aim to restore native β-cell function and achieve insulin independence. The article also discusses the potential of phytomedicines and gut microbiota modulation. This review provides insights into the unique challenges of implementing these innovations within the Chinese healthcare context, highlighting the need for high-quality clinical research, personalized strategies, and improved healthcare accessibility to enhance long-term patient outcomes.

Circular diagram illustrating treatments for Type 1 Diabetes Mellitus, segmented into insulin weekly formulation, blood glucose monitoring technology, gene editing, immune regulation, and other therapies like stem cell, curcumin, and probiotics.